Clinical Trials Logo

Chronic Obstructive Pulmonary Disease clinical trials

View clinical trials related to Chronic Obstructive Pulmonary Disease.

Filter by:

NCT ID: NCT01972776 Terminated - COPD Clinical Trials

A Safety, Tolerability and Efficacy Study in COPD Patients With QBM076.

Start date: November 2013
Phase: Phase 2
Study type: Interventional

This is a 2 Part study. Part 1 is a safety and tolerability study in GOLD I-III COPD patients. Part 2 is an efficacy study in GOLD I-III COPD patients.

NCT ID: NCT01933308 Terminated - COPD Clinical Trials

Optimization of Pulmonary Rehabilitation Programmes: the OPTION Study

OPTION
Start date: November 2008
Phase: N/A
Study type: Interventional

Chronic obstructive pulmonary disease (COPD) has a profound impact on the lives of individuals who suffer from it. Participants with COPD are often caught in a downward spiral that goes from chronic airflow limitation to invalidity and poor quality of life. Exercise training is considered the key to successful pulmonary rehabilitation (PR) because it is responsible for much of the benefits associated with this intervention. However, despite current guidelines recommend high-intensity exercise training. the optimal exercise training protocol for PR participants has yet to be determined. Aims: The main goal of the proposed research project will be to determine the optimal exercise training protocol in PR. More specifically, the objectives will be to compare the effects of continuous high-intensity training (CT80), continuous training at the ventilatory threshold (CTVT), and interval training (IT) on various PR program outcomes and to compare participant compliance to the three training regimens. Methods: One hundred and twenty subjects will be recruited. Participants who meet the eligibility criteria and accept to participate in the study will be randomized to one of three groups: the CT80 group, the CTVT group, or the IT group. Session duration will be adjusted such that the total amount of work performed per session will be comparable between the three groups. Assessments will be made at baseline (week 0), at program completion (week 12), and one year after program start (year 1). The primary outcome measure will be short-term (12 weeks) change in exercise tolerance, as measured by the endurance time to constant-load cycling. Secondary outcome measures will include: long-term (1 year) change in exercise tolerance; short-term and long-term changes in functional status, psychological status, cognition, and health-related quality of life; average participant compliance to the target intensity throughout the 12-week program; and long-term adherence to exercise recommendations. Relevance: The proposed research will inform clinicians and scientists regarding which of the exercise training protocols currently used in PR is optimal for COPD participants by examining their short-term and long-term impact on physiological, functional, psychological, neuropsychological, behavioural and quality of life outcomes. For COPD participants, our findings have the potential to improve the effectiveness of a key intervention for the management of their disease.

NCT ID: NCT01871246 Terminated - Clinical trials for Chronic Obstructive Pulmonary Disease

Acute Exacerbation of COPD and Physical Activity - Preliminary Study

Start date: February 2013
Phase:
Study type: Observational

People with chronic obstructive pulmonary disease (COPD) are very sedentary and efforts to establish an active lifestyle are challenging because of periodic acute exacerbations of COPD that interrupt physical activity patterns and contribute to further decline in physical activity. The purpose of this preliminary research is to learn more about the experience of acute exacerbations of COPD (AECOPD) from the perspective of the patient and his/her family and to learn how AECOPDs affect physical activity.

NCT ID: NCT01793649 Terminated - Clinical trials for Chronic Obstructive Pulmonary Disease

A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects

Start date: October 2012
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, cross-over, vehicle-controlled study to determine whether GS-5737 in 2.8% saline accelerates mucociliary clearance (MCC) in healthy subjects, compared to vehicle of 2.8% saline alone.

NCT ID: NCT01766544 Terminated - Asthma Clinical Trials

Asthma & COPD Guideline Implementation

Start date: September 2009
Phase: Phase 0
Study type: Interventional

This is a report of a protocol developed to improve asthma and COPD care in a primary care setting. The study was approved by an Ethics Committee and support by the Canadian Thoracic Society through an unrestrictive grant from GlaxoSmithKline. However, the study could not be done and the investigators report why, discussing the difficulties to perform such study. This information should be very useful to investigators planning this sort of study.

NCT ID: NCT01761006 Terminated - Clinical trials for Chronic Obstructive Pulmonary Disease

Evaluation of FeNO During and Following Acute COPD Exacerbation

Start date: March 2013
Phase: N/A
Study type: Observational

The purpose of this research study is to determine whether exhaled nitric oxide (FeNO) goes up during an acute exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) and whether the level of exhaled nitric oxide returns to normal in the weeks after an exacerbation.

NCT ID: NCT01760304 Terminated - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo

AZCO
Start date: January 2012
Phase: Phase 4
Study type: Interventional

To investigate whether Budesonide/Formoterol (Symbicort ®) therapy can improve heart function at rest by decreasing lung hyperinflation in patients with COPD (Chronic Obstructive Pulmonary Disease).

NCT ID: NCT01742338 Terminated - COPD Clinical Trials

Dose of Corticosteroids in COPD

DOSE
Start date: May 3, 2012
Phase: Phase 4
Study type: Interventional

COPD (chronic obstructive pulmonary disease) is a long-lasting lung disease usually caused by long-term smoking. COPD can get worse, making people sick enough to need hospitalization. Corticosteroids are very effective and are almost always used, but nobody knows the right dose. High doses may work better but could cause more side effects than low doses. Typical treatment lengths last at least one week. This study will be comparing two common regimens: either 40mg of corticosteroids daily (low dose), or 80mg of corticosteroids daily (high dose). It is unknown which regimen works better..

NCT ID: NCT01739790 Terminated - COPD Clinical Trials

N-Acetylcysteine for Patients With COPD and Chronic Bronchitis

Start date: January 2013
Phase: N/A
Study type: Interventional

N-acetylcysteine (NAC) is described as having mucolytic and antioxidant properties. It is widely prescribed for patients with chronic obstructive lung disease (COPD), particularly for those who have accompanying symptoms of chronic cough and sputum production. Compared to placebo, high-dose NAC will improve Saint George Respiratory Questionnaire scores in patients with COPD and chronic bronchitis.

NCT ID: NCT01708057 Terminated - Clinical trials for Chronic Obstructive Pulmonary Disease

A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Start date: October 2012
Phase: Phase 2
Study type: Interventional

This study in Chronic Obstructive Pulmonary Disease (COPD) patients will investigate the bronchodilatory effect of AZD8683. AZD8683 will be tested versus placebo and an active comparator.